Stockscreener 앱 받기
37.16
6.04%
-2.39
전일 마감가:
$39.55
열려 있는:
$40.33
하루 거래량:
14,846
Relative Volume:
0.52
시가총액:
$227.42M
수익:
-
순이익/손실:
$-7.12M
주가수익비율:
-16.16
EPS:
-2.3
순현금흐름:
$-6.82M
1주 성능:
-5.73%
1개월 성능:
-2.26%
6개월 성능:
+105.42%
1년 성능:
+5,918%
1일 변동 폭
$35.65
$40.33
1주일 범위
$32.97
$40.33
52주 변동 폭
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
MNPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
37.16 | 241.06M | 0 | -7.12M | -6.82M | -2.30 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-19 | 재개 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Piper Sandler | Overweight |
| 2024-10-11 | 개시 | Rodman & Renshaw | Buy |
| 2021-01-28 | 개시 | ROTH Capital | Buy |
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
Research Analysts Offer Predictions for MNPR Q2 Earnings - Defense World
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Globe and Mail
Monopar Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Monopar (MNPR) Projects Financial Stability Through 2026 | MNPR Stock News - GuruFocus
Monopar Therapeutics reports Q1 EPS (38c), consensus (57c) - TipRanks
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics SEC 10-Q Report - TradingView
2,037 Shares in Monopar Therapeutics Inc. (NASDAQ:MNPR) Acquired by JPMorgan Chase & Co. - Defense World
(MNPR) Proactive Strategies - news.stocktradersdaily.com
Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wi - GuruFocus
Monopar Therapeutics Inc expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Monopar Therapeutics Highlights ALXN1840 Data at EASL 2025 - TipRanks
Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wilson Disease | MNPR Stock News - GuruFocus
Monopar Therapeutics (MNPR) Expected to Announce Quarterly Earnings on Thursday - Defense World
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 | MNPR Stock News - GuruFocus
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 - The Manila Times
Geode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) - Defense World
Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 - Insider Monkey
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 - The Manila Times
Why These 15 Healthcare Stocks Are Surging in 2025 - Insider Monkey
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
(MNPR) Investment Analysis - news.stocktradersdaily.com
Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com
(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com
Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks
Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada
Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World
What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World
Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo
Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World
Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq
Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN
Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks
Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks
Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks
Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks
Monopar Therapeutics Inc. (MNPR) reports earnings - Quartz
Monopar Therapeutics SEC 10-K Report - TradingView
Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance
Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday - Defense World
Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha
Piper Sandler sets Monopar stock at $76 with Overweight rating - Investing.com
Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential - TipRanks
Piper Sandler sets Monopar stock at $76 with Overweight rating By Investing.com - Investing.com UK
(MNPR) Trading Report - news.stocktradersdaily.com
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 19% loss last week hit both individual investors who own 33% as well as institutions - Simply Wall St
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):